Porvair Sciences Ltd. has produced an application note that describes a method for the rapid and sensitive determination of a novel drug entity in human plasma.
Key to the high throughput of this method is the use of the Microluteâ„¢ 96-well SPE system, which allows a batch of samples to be prepared for injection in less than half the time that is actually required to analyse them. The method meets all regulatory requirements for clinical studies, and is suitable for the analysis of large numbers of samples. A copy of Application Note D may be downloaded from www.porvair-sciences.com
The developed method using the Microluteâ„¢ was validated over a concentration range of 100 to 10,000 pg /ml. Recovery using the SPE method was approximately 60%, and consistent across the calibration range. The authors describe how the Microluteâ„¢ SPE method, unlike protein precipitation sample preparation, is free from LC/MS matrix effects that may influence the ionisation of the compound(s) of interest.
Developed in conjunction with a leading pharmaceutical company the Microluteâ„¢ has become the benchmark for high throughput sample preparation across a range of applications. The innovative design of the Microluteâ„¢ from Porvair Sciences Ltd offers all the advantages of automated and high throughput SPE sample preparation in a convenient microplate format capable of rapidly processing 96 samples in one go repeatedly and precisely.
Established in 1992, Porvair Sciences Ltd. expertise in microplate technology and manufacturing covers scientific fields including Life Sciences, Drug Discovery, Combinatorial Chemistry, Solid Phase Extraction, Protein Purification, High Throughput Screening, Proteomics and Genomics. Porvair Sciences Ltd. is a wholly owned subsidiary of Porvair plc.